FibroBiologics, Inc. Common Stock – NASDAQ:FBLG
FibroBiologics, Inc. Common Stock stock price today
$0.617
-1.74
-73.87%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
FibroBiologics, Inc. Common Stock stock price monthly change
-50.21%
month
FibroBiologics, Inc. Common Stock stock price quarterly change
-50.21%
quarter
FibroBiologics, Inc. Common Stock key metrics
Market Cap | 77.98M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeFibroBiologics, Inc. Common Stock stock price history
FibroBiologics, Inc. Common Stock stock forecast
FibroBiologics, Inc. Common Stock financial statements
Average Price Target
$9
Potential upside: 1359.61%
Analysts Price target
Financials & Ratios estimates
| 2020 | 0 | -1.16M | |
|---|---|---|---|
| 2023 | 0 | -16.48M |
| 2023 | 11821000 | 10.56M | 89.4% |
|---|
| 2022 | -4.06M | 0 | 5.92M |
|---|---|---|---|
| 2023 | -6.40M | -495K | 13.79M |
FibroBiologics, Inc. Common Stock alternative data
| Mar 2024 | 10 |
|---|---|
| Apr 2024 | 10 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
| Dec 2024 | 10 |
FibroBiologics, Inc. Common Stock other data
-
What's the price of FibroBiologics, Inc. Common Stock stock today?
One share of FibroBiologics, Inc. Common Stock stock can currently be purchased for approximately $0.62.
-
When is FibroBiologics, Inc. Common Stock's next earnings date?
Unfortunately, FibroBiologics, Inc. Common Stock's (FBLG) next earnings date is currently unknown.
-
Does FibroBiologics, Inc. Common Stock pay dividends?
No, FibroBiologics, Inc. Common Stock does not pay dividends.
-
How much money does FibroBiologics, Inc. Common Stock make?
FibroBiologics, Inc. Common Stock has a market capitalization of 77.98M.
-
What is FibroBiologics, Inc. Common Stock's stock symbol?
FibroBiologics, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "FBLG".
-
What is FibroBiologics, Inc. Common Stock's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of FibroBiologics, Inc. Common Stock?
Shares of FibroBiologics, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does FibroBiologics, Inc. Common Stock have?
As Dec 2024, FibroBiologics, Inc. Common Stock employs 10 workers.
-
When FibroBiologics, Inc. Common Stock went public?
FibroBiologics, Inc. Common Stock is publicly traded company for just a year since IPO on 1 Feb 2024.
-
What is FibroBiologics, Inc. Common Stock's official website?
The official website for FibroBiologics, Inc. Common Stock is fibrobiologics.com.
-
How can i contact FibroBiologics, Inc. Common Stock?
FibroBiologics, Inc. Common Stock can be reached via phone at 281 651 5150.
-
What is FibroBiologics, Inc. Common Stock stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for FibroBiologics, Inc. Common Stock in the last 12 months, the avarage price target is $9. The average price target represents a 1359.61% change from the last price of $0.62.
FibroBiologics, Inc. Common Stock company profile:
FibroBiologics, Inc. Common Stock
fibrobiologics.comExchange:
NASDAQ
Full time employees:
10
Industry:
Biotechnology
Sector:
Healthcare
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
455 East Medical Center Boulevard
Houston, 77598
Houston, 77598
CIK: 0001958777
ISIN: US31573L1052
:
